| Authors: |
Paila YD; Moderna, Inc., Cambridge, MA, 02142, USA., Pajon R; Moderna, Inc., Cambridge, MA, 02142, USA., Banbury B; Adaptive Biotechnologies, Seattle, WA, 98109, USA., Fields P; Adaptive Biotechnologies, Seattle, WA, 98109, USA., Maglinao M; Moderna, Inc., Cambridge, MA, 02142, USA., De Rosa SC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA.; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, 98195, USA., Morris D; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA.; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, 98195, USA., Siangphoe U; Moderna, Inc., Cambridge, MA, 02142, USA., Cohen KW; Moderna, Inc., Cambridge, MA, 02142, USA. Kristen.Cohen@modernatx.com., Paris R; Moderna, Inc., Cambridge, MA, 02142, USA. robert.paris@modernatx.com. |
